Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________
Eisai, Inc., makers of the most widely prescribed Alzheimer's medication (Aricept), released a status update today on two studies they have sponsored. The indications are that they expect to bring two new formulations of Aricept to the market in the future.
First, they have concluded a successful review of phase III data on a sustained release capsule that could improve clinical outcomes by mediating the dose of the drug in the bloodstream. The company announced an intention to file and NDA (New Drug Application) with the FDA by end of summer 2009.
Eisai also announced that they are studying a transdermal patch formulation at locations in Japan and the USA. Their expectation is that an NDA for this formulation might be filed within the next 12 months.
The FDA pipeline for new Alzheimer's treatments is quite full but it is encouraging to see that those drugs already approved are also being optimized through ongoing research and development.
Subscribe to:
Post Comments
(
Atom
)
No comments :
Post a Comment